Health Care & Life Sciences » Biotechnology | Anavex Life Sciences Corp.

Anavex Life Sciences Corp. | Ownership

Companies that own Anavex Life Sciences Corp.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Park West Asset Management LLC
2,942,165
6.59%
-72,200
0.32%
06/30/2018
The Vanguard Group, Inc.
1,682,471
3.77%
-18,854
0%
06/30/2018
Knoll Capital Management LP
724,205
1.62%
0
1.68%
06/30/2018
Millennium Management LLC
667,706
1.5%
667,706
0%
06/30/2018
Goldman Sachs & Co. LLC (Private Banking)
302,832
0.68%
267,706
0%
06/30/2018
Geode Capital Management LLC
281,105
0.63%
-44,482
0%
06/30/2018
BlackRock Fund Advisors
212,660
0.48%
-1,428,137
0%
06/30/2018
Element Capital Management LLC
200,970
0.45%
200,970
0.01%
06/30/2018
Ergoteles LLC
191,571
0.43%
191,571
0.02%
06/30/2018
Susquehanna Financial Group LLLP
176,660
0.4%
114,047
0%
06/30/2018

About Anavex Life Sciences

View Profile
Address
51 West 52nd Street
New York New York 10019
United States
Employees -
Website http://www.anavex.com
Updated 07/08/2019
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.